Literature DB >> 32500646

Evolution of neuronal and glial tau isoforms in chronic traumatic encephalopathy.

Jonathan D Cherry1,2,3,4, Soong Ho Kim5, Thor D Stein1,3,4,6, Morgan J Pothast3,4, Raymond Nicks3,4,6, Gaoyuan Meng6, Bertrand R Huber3,4,6, Jesse Mez2,3,7, Michael L Alosco2,3, Yorghos Tripodis8, Kurt Farrell5, Victor E Alvarez3,4,6, Ann C McKee1,2,3,4,6, John F Crary5.   

Abstract

Chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy characterized by accumulation of hyperphosphorylated tau (p-tau) in perivascular aggregates in neurons and glia at the depths of neocortical sulci and progresses to diffuse neocortical, allocortical and brainstem structures. The strongest risk factor is exposure to repetitive head impacts acquired most commonly through contact sports and military service. Given that CTE can only be definitively diagnosed after death, a better understanding of the cellular and molecular changes in CTE brains may lead to identification of mechanisms that could be used for novel biomarkers, monitoring progression or therapeutic development. Disruption of alternative pre-mRNA splicing of tau mRNA plays a pathogenic role in tauopathy, with multiple characteristic patterns of isoform accumulation varying among tauopathies. Limited data are available on CTE, particularly at early stages. Using biochemical and histological approaches, we performed a detailed characterization of tau isoform signatures in post-mortem human brain tissue from individuals with a range of CTE stages (n = 99). In immunoblot analyses, severity was associated with decreased total monomeric tau and increased total oligomeric tau. Immunoblot with isoform-specific antisera revealed that oligomeric tau with three and four microtubule binding domain repeats (3R and 4R) also increased with CTE severity. Similarly, immunohistochemical studies revealed p-tau accumulation consisting of both 3R and 4R in perivascular lesions. When the ratio of 4R:3R was analyzed, there was mixed expression throughout CTE stages, although 4R predominated in early CTE stages (I-II), a 3R shift was observed in later stages (III-IV). While neurons were found to contain both 3R and 4R, astrocytes only contained 4R. These 4R-positive cells were exclusively neuronal at early stages. Overall, these findings demonstrate that CTE is a mixed 4R/3R tauopathy. Furthermore, histologic analysis reveals a progressive shift in tau isoforms that correlates with CTE stage and extent of neuronal pathology.
© 2020 International Society of Neuropathology.

Entities:  

Keywords:  chronic traumatic encephalopathy; gliofibrillary tangle; hyperphosphorylation; neurofibrillary tangle; tau isoform; tauopathy

Year:  2020        PMID: 32500646     DOI: 10.1111/bpa.12867

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  17 in total

1.  Tau seeding in chronic traumatic encephalopathy parallels disease severity.

Authors:  Sarah K Kaufman; Sarah Svirsky; Jonathan D Cherry; Ann C McKee; Marc I Diamond
Journal:  Acta Neuropathol       Date:  2021-10-09       Impact factor: 17.088

2.  Evidence of traumatic brain injury in headbutting bovids.

Authors:  Nicole L Ackermans; Merina Varghese; Terrie M Williams; Nicholas Grimaldi; Enna Selmanovic; Akbar Alipour; Priti Balchandani; Joy S Reidenberg; Patrick R Hof
Journal:  Acta Neuropathol       Date:  2022-05-17       Impact factor: 15.887

3.  Tau phosphorylation sites serine202 and serine396 are differently altered in chronic traumatic encephalopathy and Alzheimer's disease.

Authors:  SpiroAnthony Stathas; Victor E Alvarez; Weiming Xia; Raymond Nicks; Gaoyuan Meng; Sarah Daley; Morgan Pothast; Arsal Shah; Hunter Kelley; Camille Esnault; Robert McCormack; Erin Dixon; Lucas Fishbein; Jonathan D Cherry; Bertrand R Huber; Yorghos Tripodis; Michael L Alosco; Jesse Mez; Ann C McKee; Thor D Stein
Journal:  Alzheimers Dement       Date:  2021-12-02       Impact factor: 16.655

4.  Characterizing tau deposition in chronic traumatic encephalopathy (CTE): utility of the McKee CTE staging scheme.

Authors:  Michael L Alosco; Jonathan D Cherry; Bertrand Russell Huber; Yorghos Tripodis; Zachary Baucom; Neil W Kowall; Nicole Saltiel; Lee E Goldstein; Douglas I Katz; Brigid Dwyer; Daniel H Daneshvar; Joseph N Palmisano; Brett Martin; Robert C Cantu; Robert A Stern; Victor E Alvarez; Jesse Mez; Thor D Stein; Ann C McKee
Journal:  Acta Neuropathol       Date:  2020-08-11       Impact factor: 17.088

Review 5.  Neuroimaging Biomarkers of Chronic Traumatic Encephalopathy: Targets for the Academic Memory Disorders Clinic.

Authors:  Michael L Alosco; Julia Culhane; Jesse Mez
Journal:  Neurotherapeutics       Date:  2021-04-13       Impact factor: 7.620

6.  Tau isoforms are differentially expressed across the hippocampus in chronic traumatic encephalopathy and Alzheimer's disease.

Authors:  Jonathan D Cherry; Camille D Esnault; Zachary H Baucom; Yorghos Tripodis; Bertrand R Huber; Victor E Alvarez; Thor D Stein; Dennis W Dickson; Ann C McKee
Journal:  Acta Neuropathol Commun       Date:  2021-05-12       Impact factor: 7.578

Review 7.  Identifying degenerative effects of repetitive head trauma with neuroimaging: a clinically-oriented review.

Authors:  Breton M Asken; Gil D Rabinovici
Journal:  Acta Neuropathol Commun       Date:  2021-05-22       Impact factor: 7.801

Review 8.  Space-occupying brain lesions, trauma-related tau astrogliopathy, and ARTAG: a report of two cases and a literature review.

Authors:  Adam D Bachstetter; Filip G Garrett; Gregory A Jicha; Peter T Nelson
Journal:  Acta Neuropathol Commun       Date:  2021-03-23       Impact factor: 7.801

Review 9.  Neuroimaging Biomarkers of New-Onset Psychiatric Disorders Following Traumatic Brain Injury.

Authors:  Andrew R Mayer; Davin K Quinn
Journal:  Biol Psychiatry       Date:  2021-06-12       Impact factor: 13.382

10.  Tau Isoform Profile in Essential Tremor Diverges From Other Tauopathies.

Authors:  Soong Ho Kim; Kurt Farrell; Stephanie Cosentino; Jean-Paul G Vonsattel; Phyllis L Faust; Etty P Cortes; David A Bennet; Elan D Louis; John F Crary
Journal:  J Neuropathol Exp Neurol       Date:  2021-09-27       Impact factor: 3.148

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.